Results 121 to 130 of about 96,185 (308)

Elevated salivary levels of oxytocin persist more than seven hours after intranasal administration

Frontiers in Neuroscience, 2012
We addressed the question how long salivary oxytocin levels remain elevated after intranasal administration, and whether it makes a difference when 16 IU or 24 IU of oxytocin administration is used.
Marinus H. Van IJzendoorn, Ritu eBhandari, Rixt evan der Veen, Karen eGrewen, Marian J. Bakermans-Kranenburg   +4 more
doaj   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs

Pharmaceutics, 2018
Tadalafil is an oral selective phosphodiesterase type-5 inhibitor with demonstrated efficacy and safety that is used to treat erectile dysfunction. The purpose of this study is to compare the pharmacokinetic properties of tadalafil after conventional ...
Jeong-Soo Kim, Min-Soo Kim, In-hwan Baek
doaj   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

First-in-human intranasal [13N]oxytocin PET: evaluation of feasibility, biodistribution, and radiation dosimetry

EJNMMI Research
Background Oxytocin is a neuropeptide with therapeutic potential for several neuropsychiatric and pain-related disorders. Intranasal delivery is proposed to enable access to the central nervous system via the trigeminal nerve and olfactory nerves ...
Michael Winterdahl, Erik Nguyen Nielsen, Søren B. Hansen, André Henrique Dias, Mikkel Holm Vendelbo, Steen Jakobsen, David Yeomans   +6 more
doaj   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Validation and Application of an HPLC–UV Method for the Quantification of 3‐O‐Methylquercetin in Nasal Mucosa

ELECTROPHORESIS, EarlyView.
This study improved an HPLC–UV method for quantifying 3‐O‐methylquercetin in porcine nasal mucosa following ICH M10 and ANVISA (Brazil) guidelines, assessing selectivity, linearity, accuracy, precision, and robustness. The method was applied for the first time to evaluate release, permeation, and retention profiles of a nasal formulation.
Jeniffer Viviana Ramirez Hernández, Laura da Silva Machado, Flávia Nathiely Silveira Fachel, Sara Elis Bianchi, Elizandra Braganhol, Sheila Porto de Matos, Valquíria Linck Bassani   +6 more
wiley   +1 more source

Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication

Epilepsia, EarlyView.
Abstract Objective Appropriate endpoints for daily antiseizure medications may differ from those for intermittent, immediate‐use seizure medications (ISMs). The observed interval between seizure clusters over time (SEIzure interVAL [SEIVAL]) has been proposed as a novel effectiveness endpoint for ISMs.
Wesley T. Kerr, Katherine N. McFarlane, Leock Y. Ngo, Enrique Carrazana, Adrian L. Rabinowicz   +4 more
wiley   +1 more source